Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension

OBJECTIVE: Evaluate open-label sarilumab monotherapy in patients with rheumatoid arthritis switching from adalimumab monotherapy in MONARCH (NCT02332590); assess long-term safety and efficacy in patients continuing sarilumab during open-label extension (OLE). METHODS: During the 48-week OLE, patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd R, Strand, Vibeke, Rubbert-Roth, Andrea, Amital, Howard, Raskina, Tatiana, Gómez-Centeno, Antonio, Pena-Rossi, Claudia, Gervitz, Leon, Thangavelu, Karthinathan, St John, Gregory, Boklage, Susan, Genovese, Mark C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802992/
https://www.ncbi.nlm.nih.gov/pubmed/31673415
http://dx.doi.org/10.1136/rmdopen-2019-001017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802992/
https://www.ncbi.nlm.nih.gov/pubmed/31673415
http://dx.doi.org/10.1136/rmdopen-2019-001017

Ejemplares similares